top of page
  • Active, not recruiting

NCT02874742 : Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM - GRIFFIN

Updated: Oct 24, 2022

The GRIFFIN trial


Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Griffin Clinical Trial

The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.


Sponsor

 

ClinicalTrials.gov Identifier: NCT02874742

Official Title: Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

First Posted : August 22, 2016

Click here for details on ClinicalTrials.gov

 


 

Patient Information - FDA Approved Drugs Multiple Myeloma

 

Drug: Lenalidomide (Revlimid)

Drug: Bortezomib (Velcade)

Drug: Dexamethasone (Decadron)

Drug: Daratumumab (Darzalex)

 

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood; August 2020

 

549 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy

Hematology Disease Topics & Pathways:

multiple myeloma, Biological, antibodies, Adult, Diseases, Therapies, Plasma Cell Disorders, Lymphoid Malignancies, Study Population

Monday, December 7, 2020: 7:15 AM

 

Blood Adv; Feb 2021

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

 

RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.

 

79 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma

Hematology Disease Topics & Pathways:

Clinical Trials, Biological, Adults, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population

Saturday, December 11, 2021: 9:30 AM

 

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.

2022 ASCO Annual Meeting

June 02, 2022

 

June 28, 2022

International Myeloma Foundation

Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma

 

OAB-057 Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of GRIFFIN -Douglas Sborov


#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California


 

- Multiple locations


- Alabama: University of Alabama at Birmingham

- California: City of Hope Duarte

- Georgia: Emory University Atlanta

- Illinois: University of Chicago

- Florida: Moffitt Cancer Center Tampa

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Missouri: Washington University School of Medicine Saint Louis

- Nebraska: University of Nebraska Medical Center Omaha

- North Carolina: Levine Cancer Institute Charlotte

- North Carolina: Wake Forest Baptist Health Winston-Salem

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- Texas: UT Southwestern Medical Center Dallas

- Texas: The University of Texas MD Anderson Cancer Center Houston

 

Locations

United States, Alabama

United States, California

United States, Colorado

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Illinois

United States, Kansas

United States, Louisiana

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Missouri

United States, Nebraska

United States, New York

United States, North Carolina

United States, Ohio

United States, Oregon

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Utah

United States, Washington

United States, Wisconsin

 

RELATED POSTS


NCT03710603: Phase 3 (Perseus) EMN17 - Dara-VRd Vs VRd - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM


NCT03652064: Phase 3 (CEPHEUS) MMY3019 - Dara-VRd Vs VRd - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM


NCT04566328: Phase 3 (EQUATE) - EAA181 - Dara-VRd Vs Dara-Rd - Testing the Use of Combination Therapy in NDMM


NCT02195479: Phase 3 (ALCYONE) Dara-VMP Vs VMP - Bortezomib, Melphalan, Prednisone & Daratumumab


NCT02541383: Phase 3 (CASSIOPEIA) Dara-VTd Vs VTd - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT


NCT04268498: Phase2 (ADVANCE) Dara-KRd - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma


NCT03290950: Phase 2 (Manhattan) Dara-KRd - A Study of Daratumumab in Patients With NDMM wKRd-D


NCT02252172: Phase 3 (MAIA) Dara-Rd Vs Rd - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma


NCT03729804: Phase 3 (COBRA) - KRd Vs VRd in Patients with Newly Diagnosed Multiple Myeloma


NCT04096066: Phase 3 KRd Vs Rd - A Trial That Compare Two Treatments TIE - NDMM


NCT01402284: Phase 2 - KRd - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

 

NCT04483739: Phase 3 (Iskia) - Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Eligible for ASCT


NCT03319667: Phase 3 (IMROZ) - Isa-VRd Vs VRd - Isatuximab, Bortezomib, Lenalidomide and Dex NDMM


NCT04751877: Phase 3 (IFM2020-05) - Isa-VRd Vs Isa-Rd - Non-Frail NTE Myeloma Elderly Patients

 

NCT04923893: Phase 3 (CARTITUDE-5) VRd --> Cilta-cel Vs VRd --> Rd - NDMM- (No ASCT planned)


NCT05257083: Phase 3 (CARTITUDE-6) DVRd -> Ciltacabtagene Autoleucel Vs DVRd -> Transplant ASCT- NDMM

 

NCT01850524: Phase 3 (TOURMALINE-MM2) Ixa-Rd Vs Rd - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM





Yorumlar


Posts Archive
bottom of page